RP11-93L9.1: A Potential Drug Target and Biomarker for Diseases

Target Name: LINC01091

NCBI ID: G285419

LINC01091

Other Name(s): RP11-93L9.1 | Long intergenic non-protein coding RNA 1091, transcript variant 1 | long intergenic non-protein coding RNA 1091

RP11-93L9.1: A Potential Drug Target and Biomarker for Diseases

LINC01091 (RP11-93L9.1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the T-cell antigen receptor (TCR) family, which is a type of protein that is expressed in the immune system and plays a critical role in the immune response.

RP11-93L9.1 is a 19-kDa protein that is expressed in the brain, heart, and kidneys. It is localized to the dendrites of neurons and the cell membrane of endothelial cells. RP11-93L9.1 is also expressed in the testes , and its levels are higher in these tissues than in the brain and heart.

RP11-93L9.1 is involved in the immune response by regulating the movement of immune cells to the site of an infection or inflammation. It is known to interact with the protein PDCD1, which is also a TCR subunit that is expressed in the immune system.

RP11-93L9.1 has also been shown to play a role in the regulation of inflammation. It is known to interact with the protein NF-kappa-B, which is a transcription factor that regulates inflammation.

RP11-93L9.1 is also involved in the regulation of cell survival. It has been shown to interact with the protein p53, which is a tumor suppressor protein that is responsible for regulating cell growth and apoptosis.

RP11-93L9.1 is a potential drug target for various diseases, including cancer, autoimmune diseases, and neurodegenerative diseases. It is also a potential biomarker for these diseases, as its levels may be affected by the presence of disease.

RP11-93L9.1 is a promising drug target because it is involved in the regulation of critical immune and inflammatory processes that are involved in the development and progression of many diseases. Studies are currently being conducted to determine the effectiveness of drugs that target RP11- 93L9.1.

In conclusion, RP11-93L9.1 is a protein that is expressed in various tissues of the body and is involved in the regulation of the immune and inflammatory responses. It is a potential drug target and biomarker for various diseases, including cancer, autoimmune diseases , and neurodegenerative diseases. Further studies are needed to determine its effectiveness as a drug and its potential as a biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1091

The "LINC01091 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01091 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets